Making a difference in patients’ lives: Leading provider for critical care

The healthcare space is rapidly changing: Demographic shifts, AI advancements, and evolving patient needs. With our products and services at Fresenius Kabi, we are uniquely positioned to support patients right at the critical points in care. Whether in the emergency room, where quick decisions in diagnoses and choosing the right patient path are key, in the operating room with precise procedures, or in the intensive care unit, where stabilizing patients and safely guiding them out of critical situations is crucial.

Throughout 2024, Fresenius Kabi has significantly strengthened its role as a leading provider of healthcare products and therapies for critically and chronically ill patients: by investing in key growth areas and making a difference in patients’ lives.

Our commitment to delivering high-quality, innovative healthcare solutions is fueled by the dedication of our valued employees. Striving to become an Employer of Choice is a natural extension of this commitment and with that, ensuring that patients receive the highest standard of care. The Top Employer recognition underscores our efforts to deliver on our promise of excellence across all aspects of our organization.

2024 success stories:

Kabi’s strategy is paying off

Fresenius Kabi is strategically well-positioned with IV generics and fluids as the basis, complemented by the three growth vectors: Biopharma, Clinical Nutrition, and MedTech. Introduced in 2021, the strategic approach of focusing on the three growth vectors while strengthening the volume-driven IV generics business is paying off: The growth vectors’ share of EBIT is steadily increasing. With Kabi’s broad and unique portfolio, we are making a difference in patients’ lives by investing in areas that matter: in Nutrition, MedTech, and Biopharma. The three growth vectors are now the largest value drivers at Fresenius - a trend that is set to continue with contributions from Biopharma, new product launches in Nutrition, and the improving MedTech margin.

Growing access to essential and affordable medicine

By continuously expanding our generics business, we strengthen our role to provide access to essential and affordable medicine for a growing amount of people. We ensure the supply for critically and chronically ill patients. In 2024, we expanded our portfolio with Lacosamide, a generic for treating epilepsy in intensive care, and Thiotepa, a cancer therapy in Europe. In the U.S., launching Cyclophosphamide, an oncology product, and Cetrorelix Acetate, used for women’s health, will enhance further cost-effective treatment options.

Fresenius Kabi employee operates a machine in a production facility

Uniquely positioned with both parenteral and enteral nutrition

Clinical nutrition is a growing business with attractive margins, and we are uniquely positioned globally: We cover both parenteral and enteral nutrition. In 2024, we continuously expanded our offering. In Europe, we launched Peditrace Novum, a parenteral micronutrient formula for pediatric use. In addition, the first launches of ‘Foods for Special Medical Purposes’ (FSMP) in China offer new growth opportunities and improve access in China to innovative nutrition formulas.

Driving a new generation of generics

Affordability is key for IV generics and biopharmaceuticals! Our Biopharma portfolio plays an important role here: With Kabi’s biosimilars pipeline – biologically produced imitation products – we drive a new generation of generics. Five products are already on the market, including the launch of Tyenne, the first tocilizumab biosimilar for inflammatory and immune diseases launched in 20 countries globally. Additionally, Otulfi, our ustekinumab biosimilar, received FDA and EMA approval in 2024 and was just launched in March 2025. Biosimilars are significantly more affordable than biologics, improving access to cutting-edge treatments for acute and chronic diseases. With the biosimilar market expected to grow by 20% in the next five years, Kabi’s portfolio is well-positioned to capitalize on this expansion.

In this effort, mAbxience is an important platform for us: we are working on scaling and advancing vertical integration. With mAbxience, we have acquired a leading biopharmaceutical company that develops and manufactures biosimilars and biologics, with end-to-end capabilities in state-of-the-art facilities in Spain and Argentina. mAbxience is not only increasing our pipeline of molecules but it also complements our service offering with the highly attractive ‘Contract Development and Manufacturing Organization’ (CDMO) business. All this is contributing to 2025 and beyond!

Fresenius Kabi employee transfers liquid from a small container

Strengthening global partnerships

In MedTech, we focus on achieving the highest precision in patient care and therapy. We have strengthened our medical technology business through strong partnerships with leading companies and investments in state-of-the-art manufacturing technologies. We collaborate with Cellular Origins to automate the cell processing in cell and gene therapies. Additionally, we have completed a clinical study using enhanced software for improved plasma collection. The rollout of our smart pump system, Ivenix, in the U.S is progressing as planned, and the feedback has been very promising.

Global footprint, local strengths

While Fresenius Kabi serves global markets, our regional and local presence is one of Kabi’s strengths. This balanced strategy and a ‘local for local’ approach to customers can be seen in our manufacturing network, which spans from Wuxi in China to Friedberg in Germany to Grand Island, Melrose Park, and Wilson in the United States. A prime example for this approach is the U.S.: more than 70% of our pharmaceuticals sold to U.S. customers are produced in the country. We manage the entire supply chain, from manufacturing, logistics to warehousing and have invested in our distribution network and located them so those sites can ship product to customers within 24 hours. Through this manufacturing and distribution network, we can respond effectively in critical situations, such as recent shortages of infusion and irrigation solutions. These solutions are essential for hospital operations, and Kabi’s quick, flexible response helped keep healthcare systems running worldwide – thanks to our global production capabilities!